AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FTSE 100 rebounded after a near three-week low, boosted by gains in healthcare and industrial mining sectors. AstraZeneca's positive drug trial results and rebounding copper prices fueled the rise ...

AstraZeneca shares have enjoyed moderate gains this year, helping to recover some of last year’s losses. But does it remain a ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.